UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2009
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
| California | | 001-14758 | | 33-0476164 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
3260 Whipple Road Union City, California
(Address of Principal Executive Offices) | | 94587
(Zip Code) |
Registrant’s telephone number, including area code:(510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| þ | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01. Regulation FD Disclosure.
On April 24, 2009, Questcor Pharmaceuticals, Inc. (the “Company”), prepared and mailed, along with the Company’s proxy statement for the Company’s Annual Meeting to be held on May 29, 2009, a letter to its shareholders in the form of Exhibit 99.1 attached hereto (the “Letter to the Shareholders”), and incorporated herein by reference. The Letter to the Shareholders has been filed with the Securities and Exchange Commission as Additional Definitive Proxy Solicitation Materials.
Item 8.01. Other Events.
The information disclosed in Item 7.01 is incorporated herein by this reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Questcor Pharmaceuticals, Inc. Letter to its Shareholders, dated April 24, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| Date: April 24, 2009 | QUESTCOR PHARMACEUTICALS, INC.
| |
| | By: | /s/ Gary M. Sawka | |
| | | Gary M. Sawka | |
| | | Senior Vice-President, Finance and
Chief Financial Officer | |
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Questcor Pharmaceuticals, Inc. Letter to its Shareholders, dated April 24, 2009. |
